Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1978 2
1979 3
1980 3
1981 8
1982 8
1983 10
1984 8
1985 6
1986 11
1987 17
1988 13
1989 7
1990 9
1991 7
1992 17
1993 22
1994 22
1995 12
1996 19
1997 21
1998 18
1999 12
2000 13
2001 14
2002 17
2003 22
2004 22
2005 34
2006 32
2007 34
2008 39
2009 28
2010 39
2011 53
2012 66
2013 78
2014 65
2015 68
2016 58
2017 56
2018 54
2019 48
2020 48
2021 58
2022 61
2023 64
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,203 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
Elkader A, Sproule B. Elkader A, et al. Clin Pharmacokinet. 2005;44(7):661-80. doi: 10.2165/00003088-200544070-00001. Clin Pharmacokinet. 2005. PMID: 15966752 Review.
Naloxone has been added to a sublingual formulation of buprenorphine to reduce the abuse liability of the product. The presence of naloxone does not appear to influence the pharmacokinetics of buprenorphine. Buprenorphine crosses the placenta during pregnancy …
Naloxone has been added to a sublingual formulation of buprenorphine to reduce the abuse liability of the product. The presence of na …
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Mattick RP, Breen C, Kimber J, Davoli M. Mattick RP, et al. Cochrane Database Syst Rev. 2014 Feb 6;2014(2):CD002207. doi: 10.1002/14651858.CD002207.pub4. Cochrane Database Syst Rev. 2014. PMID: 24500948 Free PMC article. Review.
AUTHORS' CONCLUSIONS: Buprenorphine is an effective medication in the maintenance treatment of heroin dependence, retaining people in treatment at any dose above 2 mg, and suppressing illicit opioid use (at doses 16 mg or greater) based on placebo-controlled trials.However …
AUTHORS' CONCLUSIONS: Buprenorphine is an effective medication in the maintenance treatment of heroin dependence, retaining people in …
Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, Frost M, Tiberg F, Linden M, Sheldon B, Oosman S, Peterson S, Chen M, Kim S. Lofwall MR, et al. JAMA Intern Med. 2018 Jun 1;178(6):764-773. doi: 10.1001/jamainternmed.2018.1052. JAMA Intern Med. 2018. PMID: 29799968 Free PMC article. Clinical Trial.
IMPORTANCE: Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations. OBJECTIVE: To determine whether treatment involving novel weekly and monthly subcutaneous (SC) buprenorphine depot formulations is noninferior to a daily s …
IMPORTANCE: Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations. OBJECTIVE: To determin …
Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis.
Link HM, Jones H, Miller L, Kaltenbach K, Seligman N. Link HM, et al. Am J Obstet Gynecol MFM. 2020 Aug;2(3):100179. doi: 10.1016/j.ajogmf.2020.100179. Epub 2020 Jul 3. Am J Obstet Gynecol MFM. 2020. PMID: 33345863 Review.
Of the 1875 mother-baby dyads available for analysis, medications prescribed as part of the medication-assisted treatment included buprenorphine-naloxone, buprenorphine alone, methadone, or long-acting opioids. There were no serious adverse maternal or neonatal outc …
Of the 1875 mother-baby dyads available for analysis, medications prescribed as part of the medication-assisted treatment included bupren
Buprenorphine for managing opioid withdrawal.
Gowing L, Ali R, White JM, Mbewe D. Gowing L, et al. Cochrane Database Syst Rev. 2017 Feb 21;2(2):CD002025. doi: 10.1002/14651858.CD002025.pub5. Cochrane Database Syst Rev. 2017. PMID: 28220474 Free PMC article. Review.
The main comparators were clonidine or lofexidine (14 studies). Six studies compared buprenorphine versus methadone, and seven compared different rates of buprenorphine dose reduction. We assessed 12 studies as being at high risk of bias in at least one of seven dom …
The main comparators were clonidine or lofexidine (14 studies). Six studies compared buprenorphine versus methadone, and seven compar …
Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
Degenhardt L, Clark B, Macpherson G, Leppan O, Nielsen S, Zahra E, Larance B, Kimber J, Martino-Burke D, Hickman M, Farrell M. Degenhardt L, et al. Lancet Psychiatry. 2023 Jun;10(6):386-402. doi: 10.1016/S2215-0366(23)00095-0. Epub 2023 May 8. Lancet Psychiatry. 2023. PMID: 37167985
BACKGROUND: Opioid dependence is associated with substantial health and social burdens, and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for people who receive this treatment. Methadone and buprenorphine are common medications provided …
BACKGROUND: Opioid dependence is associated with substantial health and social burdens, and opioid agonist treatment (OAT) is highly effecti …
The efficacy and safety of buprenorphine for the treatment of depression: A systematic review and meta-analysis.
Riblet NB, Young-Xu Y, Shiner B, Schnurr PP, Watts BV. Riblet NB, et al. J Psychiatr Res. 2023 May;161:393-401. doi: 10.1016/j.jpsychires.2023.03.037. Epub 2023 Mar 30. J Psychiatr Res. 2023. PMID: 37019069 Free PMC article. Review.
METHODS: A meta-analysis comparing the efficacy, tolerability, and safety of buprenorphine (or combinations such as buprenorphine/samidorphan) versus control in improving symptoms in patients with depression. ...CONCLUSIONS: Buprenorphine may have a small ben …
METHODS: A meta-analysis comparing the efficacy, tolerability, and safety of buprenorphine (or combinations such as buprenorphine
Buprenorphine for treating cancer pain.
Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Schmidt-Hansen M, et al. Cochrane Database Syst Rev. 2015 Mar 31;2015(3):CD009596. doi: 10.1002/14651858.CD009596.pub4. Cochrane Database Syst Rev. 2015. PMID: 25826743 Free PMC article. Review.
SELECTION CRITERIA: We included randomised controlled trials, with parallel-group or crossover design, comparing buprenorphine (any formulation and any route of administration) with placebo or an active drug (including buprenorphine) for cancer background pain in ad …
SELECTION CRITERIA: We included randomised controlled trials, with parallel-group or crossover design, comparing buprenorphine (any f …
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Mattick RP, Kimber J, Breen C, Davoli M. Mattick RP, et al. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207. doi: 10.1002/14651858.CD002207.pub3. Cochrane Database Syst Rev. 2008. Update in: Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207. doi: 10.1002/14651858.CD002207.pub4. PMID: 18425880 Updated. Review.
Low dose methadone is more likely to retain patients than low dose buprenorphine (RR= 0.67; 95% CI: 0.52 - 0.87). Medium dose buprenorphine does not retain more patients than low dose methadone, but may suppress heroin use better. There was no advantage for medium d …
Low dose methadone is more likely to retain patients than low dose buprenorphine (RR= 0.67; 95% CI: 0.52 - 0.87). Medium dose bupr
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Mattick RP, Kimber J, Breen C, Davoli M. Mattick RP, et al. Cochrane Database Syst Rev. 2004;(3):CD002207. doi: 10.1002/14651858.CD002207.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207. doi: 10.1002/14651858.CD002207.pub3. PMID: 15266465 Updated. Review.
Low dose buprenorphine is not superior to low dose methadone. High dose buprenorphine does not retain more patients than low dose methadone, but may suppress heroin use better. There was no advantage for high dose buprenorphine over high dose methadone in ret …
Low dose buprenorphine is not superior to low dose methadone. High dose buprenorphine does not retain more patients than low d …
1,203 results